{"slug":"ghrp-6","seoKey":"ghrp6","displayName":"GHRP-6","codes":["SKF-110679"],"synonyms":["GHRP6","GHRP 6","growth hormone-releasing peptide 6","GH-releasing peptide-6","growth hormone releasing hexapeptide","SK&F 110679","U-75799E","[His1,Lys6]GHRP","Hexapeptide-2","Hexapeptid-2","Melanostatine 2","His-D-Trp-Ala-Trp-D-Phe-Lys-NH2","L-Histidyl-D-tryptophyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamid"],"legalClass":"research_chemical","identifiers":{"cas":"87616-84-0","pubchemCid":9919153,"unii":"4H7N4I6X6A","inchikey":"WZHKXNSOCOQYQX-FUAFALNISA-N","chemblId":"CHEMBL105462","wikidataQid":"Q5611751","formula":"C46H56N12O6","molecularWeight":873,"sequence":"His-D-Trp-Ala-Trp-D-Phe-Lys-NH2"},"approvals":[{"market":"US","status":"not_approved","note":"Not approved, and the negative finding rests on five separate queries run on 2026-09-10. The drug label API returned HTTP 404 for this substance, so no product information text of any approved or registered preparation names it. The national drug code database returned exactly three records, all marked as bulk ingredient registrations rather than finished medicines. The enforcement database returned thirteen records, all of them compounded preparations from United States compounding pharmacies between 2013 and 2018, eleven in hazard class II and two in class I; twelve were recalled for lack of sterility assurance and one for a positive microbial finding. All thirteen combined this substance with sermorelin, six of them additionally with GHRP-2, and none carried a brand name. Independently of that history, the agency has listed the substance since 2023-09-29 in category 2 of the bulk substances nominated under section 503B, meaning substances it considers to present significant safety risks; unlike the GHRP-2 entry, this one is not limited to particular routes of administration, and its stated reasons name effects on cortisol and insulin sensitivity rather than merely absent data. A control query for the cosmetic ingredient name of the same sequence returned twenty records, all cosmetic or dermatological products. Warning letters could not be checked in this session because that search is rendered client-side, so none are claimed either way.","date":"2023-09-29","source":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks"},{"market":"EU","status":"not_approved","note":"Not approved: no centrally authorised medicinal product. The finding is honest about its limits — the regulator's full-text search returned HTTP 401 from this environment on 2026-09-10 and its medicines API returned an antibot page, so no register query of its own backs this. It rests instead on the absence of an international nonproprietary name, the absence of an ATC code, the absence of any registration in every register that could be queried, and a 2026 review that expressly counts this substance among those marketed as research compounds without regulatory approval. A separate cosmetics layer exists: the same sequence is used as an ingredient under its cosmetic name, but the European cosmetic ingredient database could not be queried on 2026-09-10 either.","date":"2026-09-10","source":"https://www.ema.europa.eu/en/medicines?search_api_fulltext=GHRP-6"},{"market":"DE","status":"not_approved","note":"Not approved on two levels, and the second one is stricter here than for GHRP-1. Under medicines law there is neither a centralised nor a national marketing authorisation, so no finished medicinal product containing the substance may be manufactured, placed on the market or administered as a medicine. Under anti-doping law the annex to section 2(3) of the anti-doping act names it EXPRESSLY: part II.2.4 lists, under peptides acting like growth hormone releasing factors, the examples GHRP-2 (pralmorelin), GHRP-2-Gly, GHRP-6, GHRP-6-Gly and hexarelin. This substance is therefore caught by name rather than by a collective clause, and together with its glycine-extended grey-market variant. The possession and acquisition offences of section 2 of that act apply directly in the quantities set out there.","date":"2026-09-10","source":"https://www.gesetze-im-internet.de/antidopg/anlage.html"},{"market":"UK","status":"not_approved","note":"Not approved: no marketing authorisation known, and unlicensed peptide preparations fall under the general rules for unauthorised medicines in the Human Medicines Regulations 2012. The finding is of limited depth — the regulator's product database returned HTTP 200 on 2026-09-10 but delivered only the client-side search shell, with no result list in the embedded data structure, so the absence of hits is not backed by a server-rendered register query.","date":"2026-09-10","source":"https://products.mhra.gov.uk/search/?search=GHRP-6"},{"market":"AU","status":"scheduled","date":"2026-05-28","note":"The strictest documented classification of any market, quoted verbatim rather than inferred, and reached by name rather than through a class entry. The Poisons Standard carries two Schedule 4 entries directly beneath one another, one for growth hormone releasing peptides as a class and one for this substance in its own right, both marked with a hash that points to Appendix D. In the Appendix D table the class entry is item 19, worded to cover those peptides including the ones separately specified in Schedule 4, and this substance follows immediately as item 20. The instrument's substance index confirms both assignments, Schedule 4 and Appendix D clause 5. Clause 5 of that appendix is headed poisons for which possession without authority is illegal, so bare possession without authorisation is unlawful here, not merely supply. Hexarelin appears separately as item 22 and pralmorelin, that is GHRP-2, as item 30. No registered finished product is known, though the product register itself timed out on 2026-09-10 and that part is an assessment rather than a register finding.","source":"https://www.legislation.gov.au/F2026L00633/asmade"},{"market":"CA","status":"not_approved","note":"Not approved: the active-ingredient query on growth hormone releasing returned an empty array from the drug product database on 2026-09-10, so no authorised product contains the substance. The country has nonetheless been touched by it: the class I recall D-0228-2017, a sermorelin and GHRP-6 compounded preparation withdrawn for microbial contamination identified as Bacillus circulans, had been distributed to Massachusetts, New York, New Jersey, Florida and Canada.","date":"2026-09-10","source":"https://health-products.canada.ca/api/drug/activeingredient/?ingredientname=growth%20hormone%20releasing"},{"market":"CH","status":"not_approved","note":"Not approved: no marketing authorisation known. The finding is of limited depth — no register could be queried with an evaluable result list in this session on 2026-09-10, so it is an inference from the worldwide absence of any authorisation rather than a register finding of its own. The substance has nonetheless reached this market: the recall D-0364-2016 concerned a sermorelin, GHRP-6 and GHRP-2 compounded preparation whose stated distribution area expressly included Switzerland alongside the United States. Independently of that, distributing or brokering unauthorised medicinal products is unlawful here.","date":"2026-09-10","source":"https://www.swissmedicinfo.ch/"}],"devStage":"phase3","strongestEvidence":"rct_phase3","wada":{"status":"prohibited","section":"S2.2.4","listYear":2026,"source":"https://www.wada-ama.org/en/prohibited-list"},"trials":[],"sameAs":["https://www.wikidata.org/wiki/Q5611751","https://pubchem.ncbi.nlm.nih.gov/compound/9919153"],"lastVerified":"2026-09-10","version":"1.0","published":true,"locale":"en","title":"GHRP-6: what the studies show, status and safety","summary":"GHRP-6 is a lab-made peptide of six building blocks that makes the pituitary gland release a burst of growth hormone. Cyril Bowers and Frank Momany described it in 1984, and it is the oldest member of its family. Roughly two dozen small human studies followed, almost all of them single test doses measuring a hormone level. No country has approved it, and the world anti-doping list names it. The American medicines agency placed it in its risk category for compounding in 2023, after thirteen recalls of pharmacy-made injections.","updated":"2026-09-10","url":"https://mypep.app/peptides/ghrp-6"}